Quick Answer
Clearside Biomedical, Inc. reported R&D Expense of $18.59 million for fiscal year 2024.
Clearside Biomedical, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $18.59M | -10.8% |
| 2023 | $20.85M | +6.2% |
| 2022 | $19.63M | +5.9% |
| 2021 | $18.54M | +23.0% |
| 2020 | $15.07M | -3.7% |
| 2019 | $15.66M | -77.1% |
| 2018 | $68.29M | +39.2% |
| 2017 | $49.05M | +152.1% |
| 2016 | $19.45M | +80.8% |
| 2015 | $10.76M | +60.8% |
| 2014 | $6.69M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.93M | -28.9% | +85.2% |
| June 30, 2025 | $1.58M | -65.6% | -64.5% |
| March 31, 2025 | $4.46M | -20.5% | +8.1% |
| September 30, 2024 | $4.13M | -19.6% | -10.3% |
| June 30, 2024 | $4.60M | -7.0% | -18.0% |
| March 31, 2024 | $5.62M | +26.2% | +9.4% |
| September 30, 2023 | $5.13M | +10.7% | +3.8% |
| June 30, 2023 | $4.95M | -8.9% | +11.2% |
- Clearside Biomedical, Inc. showed a decrease of -10.8% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2024 period, Clearside Biomedical, Inc.’s r&d expense has grown by 177.8% (from $6.69 million to $18.59 million).
- The most recent figure is from Clearside Biomedical, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: